Jump to content

Study register

Participants and designs in PT-141 research

The number beside a study tells only part of the story. Who entered it, and what comparison survived, matter just as much.

Controlled trials: 1267 women

RECONNECT comprised two identical Phase 3 randomized controlled trials in premenopausal women with HSDD. Across 1267 participants and 24 weeks, both trials met their desire and distress endpoints. Bremelanotide 1.75 mg was administered subcutaneously as needed. Nausea, flushing and headache were the most common adverse events.

This is the strongest comparative evidence in the collection. The repeated result under the same design is the reason these trials get the greatest weight from me. That confidence concerns the measured outcomes in the population studied; applying it to a different population takes another evidential step.

1267
Premenopausal women with HSDD
24
Weeks in the controlled comparison

Open-label follow-up: 684 women

The 52-week extension enrolled 684 women, reported sustained desire improvements and found no new safety signals. It also documented drug-related nausea at 40.4%, flushing at 20.6% and headache at 12.0%.

The change in design deserves its own line in the register: participants knew the treatment, and the extension supplies no continuing blinded placebo comparison. The follow-up earns its place in my judgement of persistence and tolerability. A second year of the same controlled comparison would have answered a different question.

Brain imaging: 31 women

In the crossover fMRI experiment, 31 premenopausal women with HSDD took part in randomized, double-blind, placebo-controlled testing. MC4R agonism increased desire for up to 24 hours and altered brain processing of erotic stimuli. The crossover design compared treatments within participants.

Its scale and purpose differ from RECONNECT. The imaging result helps connect the biological target with sexual processing. The larger controlled trials do more to persuade me about average clinical improvement than a vivid brain image.

Earlier development and animal work

The 2003 pharmacology paper spans rats, nonhuman primates and men with ED. The female-rat study concerns selective solicitation behaviour. The 2025 hamster study concerns sexual reward in an animal model. These observations address different questions and cannot be pooled into a head count of human evidence.

The 2004 development profile describes a nasal spray for erectile and female sexual dysfunction, before the later injectable approval. The historical review traces PT-141 to melanotan-II and its tanning-research origins. The route and intended population both changed during development.

Approval and supporting studies

The prescribing information establishes the approved indication, dose record, pharmacokinetics and cardiovascular contraindications. The first-approval review and the review of 2019 peptide approvals place bremelanotide in its regulatory history. A review of HSDD pathways discusses excitatory melanocortin signalling.

Other entries have narrower jobs: rabbit tissue preparations test peripheral muscle effects; ambulatory monitoring examines blood pressure; a Phase 1 study in healthy adults examines tolerability, including coadministration with ethanol; and the integrated safety analysis surveys the clinical programme. Healthy-adult safety testing alone cannot establish safety in cardiovascular disease.

The separate appetite trials, melanocortin-receptor review, LiverTox monograph, forensic analysis and Melanotan II toxicity report each have their own population or material. The last concerns a related peptide, and its harm cannot be relabelled as a bremelanotide case. All entries remain in the complete reading list.